Table 1 Clinical characteristic and cardiac findings in patients with Multisystem Inflammatory Syndrome in Children in Michigan stratified by ICU admission, April 2020–February 2021
Demographic Characteristics | |||||
|---|---|---|---|---|---|
| Â | Â | Total (%) | Group 1 (PICU) (%) | Group 2 (non-PICU) (%) | p values |
Total | Â | 26 | 15 | 11 | |
Age (months) | Mean (St Dev) | 105.15 (57.3) | 99.13 (53.4) | 113.36 (64.0) | 0.5424 |
Sex | Male | 16 (61.5) | 7 (46.7) | 9 (81.8) | 0.1092 |
Female | 10 (38.5) | 8 (53.3) | 2 (18.2) | Â | |
Race | White | 14 (53.5) | 8 (53.3) | 6 (54.6) | – |
Black | 4 (15.4) | 4 (26.7) | 0 (0) | – | |
Hispanic | 3 (11.5) | 2 (13.3) | 1 (9.1) | – | |
Other | 3 (11.5) | 0 (0) | 3 (27.3) | – | |
Unknown | 2 (7.7) | 1 (6.7) | 1 (9.1) | – | |
BMI | Median (IQR) | 18.095 (16.1–20.83) | 17.7 (16.1–20.06) | 19.16 (15.44–22.98) | 0.5858 |
Clinical presentation | |||||
 Fever |  | 26 (100) | 15 (100) | 11(100) | 1.0 |
GI symptoms | Vomiting | 19 (73.1) | 12 (80) | 7 (63.6) | 0.4065 |
Diarrhea | 14 (53.9) | 7 (46.7) | 7 (63.6) | 0.3912 | |
Abdominal pain | 22 (84.6) | 14 (93.3) | 8 (72.7) | 0.2789 | |
 Skin rash |  | 15 (57.7) | 8 (53.3) | 7 (63.6) | 0.7007 |
Other Kawasaki-like featuresa | 17 (65.4) | 8 (53.3) | 9 (81.8) | 0.1315 | |
Cardiac involvement | Coronary dilation | 12 (46.2) | 6 (40) | 6 (54.6) | 0.4623 |
Other cardiac changes | 15 (57.7) | 11 (73.3) | 4 (36.4) | 0.1089 | |
History of COVID-19 infection/exposure | Â | 17 (65.4) | 7 (46.7) | 10 (90.9) | 0.0362* |
Cytokine elevationb | IL-2 Soluble | 8 (50) | 4 (40) | 4 (66.7) | 0.6084 |
IL-2 Receptor | 12 (75) | 9 (90) | 3 (50) | 0.1181 | |
IL-5 | 2 (12.5) | 2 (20) | 0 (0) | 0.5 | |
IL-6 | 7 (43.8) | 6 (60) | 1 (16.7) | 0.1451 | |
IL-10 | 16 (100) | 10 (100) | 6 (100) | Â | |
IL-13 | 6 (37.5) | 5 (50) | 1 (16.7) | 0.3069 | |
IL-17 | 5 (31.3) | 4 (40) | 1 (16.7) | 0.5879 | |
TNF-alpha | 3 (18.8) | 2 (20) | 1 (16.7) | 1.0 | |
TNF-gamma | 6 (37.5) | 4 (40) | 2 (33.3) | 1.0 | |
Positive COVID-19 PCR on admission | Â | 11 (42.3) | 6 (40) | 5 (45.5) | 1.0 |
COVID-19 antibody | Anti-Spike | 25 (96.2) | 15 (100) | 10 (90.9) | 0.4231 |
Anti-Nucleocapsid | 18 (85.7) | 10 (83.3) | 8 (88.9) | 1.0 | |
Respiratory support | Nasal cannula | 2 (7.7) | 2 (13.3) | 0 (0) | – |
BiPap | 2 (7.7) | 2 (13.3) | 0 (0) | – | |
Intubated | 8 (30.8) | 8 (53.3) | 0 (0) | – | |